Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
ipo
6
×
life sciences
national blog main
boston top stories
cancer
national top stories
san francisco blog main
san francisco top stories
clinical trials
new york blog main
new york top stories
sanofi
cancer drugs
deals
fda
san diego blog main
san diego top stories
san francisco
startups
third rock ventures
venture capital
warp drive bio
biogen
boulder/denver blog main
boulder/denver top stories
deerfield management
detroit blog main
detroit top stories
drug discovery
europe blog main
europe top stories
gilead sciences
indiana blog main
indiana top stories
investing
melinta therapeutics
national
novartis
What
medicines
6
×
ipo
bio
cancer
covid
deal
new
proteins
research
revolution
roundup
today
acquisitions
activity
aiming
ambys
announced
approvals
big
biogen
biotech
cancer’s
ceo
clamped
collabs
company’s
control
course
daniel
deadly
debuted
delays
despite
developing
development
discover
disease
diseases
drug
economic
Language
unset
Current search:
medicines
×
ipo
×
@xconomy.com
3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?